United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate 4 ug in 1 ml - hemophilia a: desmopressin acetate injection 4 mcg/ml is indicated for patients with hemophilia a with factor viii coagulant activity levels greater than 5%. desmopressin acetate injection will often maintain hemostasis in patients with hemophilia a during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. desmopressin acetate injection will also stop bleeding in hemophilia a patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. in certain clinical situations, it may be justified to try desmopressin acetate injection in patients with factor viii levels between 2% to 5%; however, these patients should be carefully monitored. von willebrand’s disease (type i): desmopressin acetate injection 4 mcg/ml is indicated for patients with mild to moderate classic von willebrand’s disease (type i) with factor viii levels greater than 5%. desmopressin acetate injection will often ma

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate 0.1 mg in 1 ml - central cranial diabetes insipidus: desmopressin nasal spray solution, usp 0.01% is indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. it is ineffective for the treatment of nephrogenic diabetes insipidus.   the use of desmopressin nasal spray solution, usp 0.01% in patients with an established diagnosis will result in a reduction in urinary output with increase in urine osmolality and a decrease in plasma osmolality. this will allow the resumption of a more normal life-style with a decrease in urinary frequency and nocturia.   there are reports of an occasional change in response with time, usually greater than 6 months. some patients may show a decreased responsiveness, others a shortened duration of effect. there is no evidence this effect is due to the development of binding antibodies but may be due to a local inactivation of the p

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

apotex inc. - desmopressin (desmopressin acetate) - tablets - 0,1mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

apotex inc. - desmopressin (desmopressin acetate) - tablets - 0,2mg

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - desmopressin acetate trihydrate 0.6mg equivalent to desmopressin 0.089 mg/ml;   - nasal spray solution - 0.1 mg/ml - active: desmopressin acetate trihydrate 0.6mg equivalent to desmopressin 0.089 mg/ml   excipient: chlorobutanol hemihydrate hydrochloric acid nitrogen purified water sodium chloride

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate injection is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. limitations of use: desmopressin acetate is ineffective and not indicated for the treatment of nephrogenic diabetes insipidus. desmopressin acetate injection is indicated for patients with hemophilia a with factor viii coagulant activity levels greater than 5% without factor viii antibodies to: ·         maintain hemostasis during surgical procedures and postoperatively ·         reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. desmopressin acetate injection is indicated for patients with mild to moderate von willebrand’s disease (type i) with factor viii levels greater than 5% to: ·         maintain hemostasis during surgical procedures and postoperatively ·     

Ireland - English - HPRA (Health Products Regulatory Authority)

ferring ireland ltd - desmopressin acetate - nasal drops, solution - 100 microgram(s)/millilitre - vasopressin and analogues; desmopressin

Malta - English - Medicines Authority

p & d pharmaceuticals limited 38 woolmer way, bordon hampshire gu35 9qf, united kingdom - desmopressin acetate - solution - desmopressin acetate 0.01 % (v/v) - pituitary and hypothalamic hormones and analogues

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin, quantity: 240 microgram (equivalent: desmopressin acetate, qty 272 microgram) - wafer - excipient ingredients: mannitol; citric acid; gelatin - 1- cranial diabetes insipidus. 2- primary nocturnal enuresis in patients from 6 years of age with normal ability to concentrate urine who are refractory to an enuresis alarm or in whom the enuresis alarm is contraindicated or inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin, quantity: 120 microgram (equivalent: desmopressin acetate, qty 136 microgram) - wafer - excipient ingredients: citric acid; mannitol; gelatin - 1- cranial diabetes insipidus. 2- primary nocturnal enuresis in patients from 6 years of age with normal ability to concentrate urine who are refractory to an enuresis alarm or in whom the enuresis alarm is contraindicated or inappropriate.